Rein Therapeutics, Inc. Common Stock (RNTX)

• Market cap: $43.8M
• 1 day: 4.12%
• 5 days: -3.35%
• 1 month: -14.04%
• 3 months: -10.62%
• 6 months: -26.28%
• Year to date: -10.22%
• 1 year: -63.73%
• 5 years: -67.42%
• 10 years: -99.06%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.

Employees: 3

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

4.96% more ownership

Funds ownership: 21.25% [Q3] → 26.21% (+4.96%) [Q4]

3% less funds holding

Funds holding: 32 [Q3] → 31 (-1) [Q4]

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

20% less capital invested

Capital invested by funds: $16.3M [Q3] → $13.1M (-$3.22M) [Q4]